Achieving ethical integration in the development of novel neurotechnologies
在新型神经技术的开发中实现伦理整合
基本信息
- 批准号:9924887
- 负责人:
- 金额:$ 16.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-13 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptionAffectAffectiveBRAIN initiativeBasal GangliaBehaviorBioethicsBrainCaregiversClinicClinicalCollaborationsConceptionsDataDeep Brain StimulationDevelopmentDevicesDisciplineDrug resistanceElectrophysiology (science)ElementsEmotionsEngineeringEpilepsyEthicistsEthicsEthnographyEvaluationExcisionFamilyFeelingFocus GroupsFundingFutureGoalsGuidelinesHumanHuman Subject ResearchImplantInstitutional Review BoardsInterventionInterviewInvestigationLawsMeasuresMedicineMental DepressionMental disordersMethodsModelingMonitorMoodsNeurosciencesOwnershipParkinson DiseasePathway interactionsPatient MonitoringPatientsPersonalityPhilosophyPopulationPublic HealthQualitative MethodsRegulationResearchResearch PersonnelResearch Project GrantsSeizuresSeveritiesShapesSocial SciencesSystemTechnical ExpertiseTechniquesTechnologyThinkingTimeWorkbrain surgeryclinical applicationclinical carecohesioncomorbid depressioncomparativedeep brain stimulatordesignexperiencefrontiergray matterinnovationinsightneural correlateneuroethicsneuropsychiatric disorderneuropsychiatryneuroregulationneurosurgeryneurotechnologynew technologynovelnovel therapeuticsprogramsrecruitstandard caretechnology developmenttherapy designtreatment strategy
项目摘要
PROJECT SUMMARY/ABSTRACT
New technologies that modulate brain function have tremendous potential for alleviating the persistent burden
of depression and other neuropsychiatric disorders, but also raise challenging ethical and societal questions
regarding self-ownership and control over our thoughts, emotions and actions. For these reasons, the
President’s Bioethics Commission and other experts have called for the integration of ethics and
neuroscience from the earliest stages of research. Such integration requires collaboration across humanistic
and scientific disciplines; and for this work to effectively shape the future ethical development of the field, it
must also actively engage patients and researchers at the forefront of novel neurotechnologies. The need for
ethical integration in neuroscience will be addressed by a cohesive interdisciplinary team with expertise in
neuroscience, clinical care, law, philosophy and social science. This work will be embedded in one of the two
teams funded by DARPA as part of the BRAIN Initiative to develop implantable “closed-loop” devices that will
both monitor and adaptively modify brain systems involved in mood and behavior regulation. Such
embedding will facilitate the overall goal of enabling the successful development and adoption of needed new
treatments for neuropsychiatric illness by recognizing, communicating, and incorporating the ethical concerns
of patients and other stakeholders into the design of neurotechnological therapies. Innovative comparative
ethnographic techniques will be applied in populations at the clinical frontier of human neurotechnology, in
pursuit of three specific aims: 1) Elicit ethical concerns in existing clinical applications of closed-loop
neuromodulation; 2) Elicit ethical concerns in investigational research on closed-loop neuromodulation of
mood; and 3) Assess the influence of disciplinary backgrounds on investigators’ evaluation of ethical
concerns. Aim 1 will focus on clinic patients with drug-resistant epilepsy undergoing NeuroPace stimulation,
the only form of closed-loop brain modulation currently approved for clinical use. Aim 2 will focus on research
patients with Parkinson’s disease and comorbid depression in a DARPA-sponsored research project to
measure and modify neural correlates of mood using a novel implanted deep brain stimulator. Aim 3
addresses how these patient experiences and concerns can be incorporated in clinicians’ and researchers’
views about the ethical development of neurotechnology. The approach is innovative, as embedding an
interdisciplinary team with expertise in advanced qualitative methods directly in a DARPA-funded
neurotechnology program will facilitate the incorporation of ethical concerns in the earliest stages of
technology development. The proposed research is significant, because it addresses core ethical and societal
concerns that will affect the acceptability of closed-loop neuromodulation of mood, a core element of the
BRAIN Initiative, and that will likely continue to grow along with our advancing ability to manipulate the human
brain.
项目总结/摘要
调节大脑功能的新技术在减轻持续负担方面具有巨大潜力
抑郁症和其他神经精神疾病,但也提出了具有挑战性的伦理和社会问题,
关于自我所有权和控制我们的思想,情绪和行动。由于这些原因,
总统的生物伦理委员会和其他专家呼吁将伦理和
神经科学从最早的研究阶段。这种整合需要跨人文学科的协作
和科学学科;为了使这项工作有效地塑造该领域未来的伦理发展,
还必须积极地让患者和研究人员参与到新神经技术的前沿。需要
神经科学的伦理整合将由一个具有以下专业知识的跨学科团队来解决:
神经科学、临床护理、法律、哲学和社会科学。这项工作将嵌入其中的两个
由DARPA资助的团队作为BRAIN计划的一部分,开发可植入的“闭环”设备,
都能监控并自适应地改变涉及情绪和行为调节的大脑系统。等
嵌入将有助于实现成功开发和采用所需新技术的总体目标,
通过认识、沟通和纳入伦理问题来治疗神经精神疾病
患者和其他利益相关者参与神经技术疗法的设计。创新比较
人种学技术将应用于人类神经技术临床前沿的人群,
追求三个具体目标:1)在现有的闭环临床应用中引发伦理问题
神经调节; 2)在闭环神经调节的调查研究中引起伦理问题,
评估学科背景对研究者道德评价的影响
性问题目的1将重点关注接受NeuroPace刺激的耐药癫痫临床患者,
这是目前被批准用于临床的唯一一种闭环大脑调节形式。目标2将侧重于研究
在DARPA赞助的一项研究项目中,
使用一种新型的植入式脑深部刺激器来测量和修改情绪的神经相关性。目标3
解决了如何将这些患者的经验和关注纳入临床医生和研究人员的
关于神经技术伦理发展的观点。这种方法是创新的,因为嵌入了一个
跨学科团队,直接在DARPA资助的一个高级定性方法的专业知识
神经技术计划将有助于在最早阶段纳入伦理问题,
技术开发。拟议的研究是重要的,因为它解决了核心的道德和社会问题。
这些问题将影响情绪闭环神经调节的可接受性,这是情绪调节的核心要素。
大脑计划,这将可能继续增长沿着我们先进的能力,以操纵人类
个脑袋
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Winston Chiong其他文献
Winston Chiong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Winston Chiong', 18)}}的其他基金
Anticipating ethical challenges and disparities in the dissemination of novel neurotechnologies
预测新型神经技术传播中的伦理挑战和差异
- 批准号:
10448454 - 财政年份:2021
- 资助金额:
$ 16.06万 - 项目类别:
Anticipating ethical challenges and disparities in the dissemination of novel neurotechnologies
预测新型神经技术传播中的伦理挑战和差异
- 批准号:
10612461 - 财政年份:2021
- 资助金额:
$ 16.06万 - 项目类别:
Anticipating ethical challenges and disparities in the dissemination of novel neurotechnologies
预测新型神经技术传播中的伦理挑战和差异
- 批准号:
10283140 - 财政年份:2021
- 资助金额:
$ 16.06万 - 项目类别:
Decision-making abilities in Alzheimer's disease and related dementias: From clinical standards to decision neuroscience
阿尔茨海默病和相关痴呆症的决策能力:从临床标准到决策神经科学
- 批准号:
10595115 - 财政年份:2018
- 资助金额:
$ 16.06万 - 项目类别:
Decision-making abilities in Alzheimer's disease and related dementias: From clinical standards to decision neuroscience
阿尔茨海默病和相关痴呆症的决策能力:从临床标准到决策神经科学
- 批准号:
10400141 - 财政年份:2018
- 资助金额:
$ 16.06万 - 项目类别:
Decision-making abilities in Alzheimer's disease and related dementias: From clinical standards to decision neuroscience
阿尔茨海默病和相关痴呆症的决策能力:从临床标准到决策神经科学
- 批准号:
10165443 - 财政年份:2018
- 资助金额:
$ 16.06万 - 项目类别:
Decision-making abilities in Alzheimer's disease and related dementias: From clinical standards to decision neuroscience
阿尔茨海默病和相关痴呆症的决策能力:从临床标准到决策神经科学
- 批准号:
9764242 - 财政年份:2018
- 资助金额:
$ 16.06万 - 项目类别:
Decision-making abilities in Alzheimer's disease and related dementias: From clinical standards to decision neuroscience
阿尔茨海默病和相关痴呆症的决策能力:从临床标准到决策神经科学
- 批准号:
9927960 - 财政年份:2018
- 资助金额:
$ 16.06万 - 项目类别:
Decision-making abilities in Alzheimer's Disease and related dementias: From clinical standards to decision neuroscience
阿尔茨海默病和相关痴呆症的决策能力:从临床标准到决策神经科学
- 批准号:
10429610 - 财政年份:2018
- 资助金额:
$ 16.06万 - 项目类别:
Neuroeconomics of Framing Effects and Risk Attitudes in Early Dementia
早期痴呆症的框架效应和风险态度的神经经济学
- 批准号:
8848017 - 财政年份:2013
- 资助金额:
$ 16.06万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 16.06万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 16.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 16.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 16.06万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 16.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 16.06万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 16.06万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 16.06万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 16.06万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 16.06万 - 项目类别:
Standard Grant